Global Information
회사소개 | 문의 | 위시리스트

암 지지요법 약제 시장 : 규모, 점유율, 동향 분석 - 치료 클래스별(G-CSF, 비스포스포네이트, 제토제, 오피오이드, NSAID, ESA), 지역별, 부문별 예측(2019-2026년)

Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And Segment Forecasts, 2019 - 2026

리서치사 Grand View Research, Inc.
발행일 2019년 06월 상품 코드 820533
페이지 정보 영문 110 Pages
가격
US $ 5,950 ₩ 7,043,000 Unprintable PDF by E-mail (Single User License)
US $ 6,950 ₩ 8,227,000 Printable PDF by E-mail (5-User License)
US $ 8,950 ₩ 10,595,000 Printable PDF by E-mail (Enterprise License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



암 지지요법 약제 시장 : 규모, 점유율, 동향 분석 - 치료 클래스별(G-CSF, 비스포스포네이트, 제토제, 오피오이드, NSAID, ESA), 지역별, 부문별 예측(2019-2026년) Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And Segment Forecasts, 2019 - 2026
발행일 : 2019년 06월 페이지 정보 : 영문 110 Pages

세계의 암 지지요법 약제 시장 규모는 향후 연평균 복합 성장률(CAGR) 1.0%로 확대되어 2026년까지 229억 달러에 이를 것으로 예측됩니다. 암 보조요법에서는 증상 예방과 관리, 암 부작용과 치료에 초점을 맞춥니다.

세계의 암 지지요법 약제(Cancer Supportive Care Drugs) 시장에 대해 조사했으며, 시장 동향과 부문별 동향, 지역별 예측, 시장 진출기업 개요에 대해 정리했습니다.

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

  • 시장 전망
  • 침투 및 성장 전망 매핑
  • 제품 파이프라인 분석
  • 혁신적 약제의 임상 프로파일
  • 규제 프레임워크
  • 시장 동향
  • 특허 만료 분석
  • 시장 분석 수단

제4장 약제 클래스별 시장

  • 정의와 범위
  • 시장 점유율 분석
  • 부문 개요
  • 시장 규모, 예측, 동향 분석
    • G-CSF
    • 에리스로포이에틴 자극제(ESA)
    • 제토제
    • 비스포스포네이트
    • 오피오이드
    • NSAID 기타

제5장 지역별 시장 분석

  • 시장 점유율 분석
  • 지역별 시장 개요
  • SWOT 분석
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 규모와 예측, 동향 분석

제6장 경쟁 분석

  • 최근 발전과 영향 분석
  • 벤더 환경
  • 주요 기업 개요
LSH 19.08.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 Cancer supportive care market - Therapeutic classes
  • Table 3 Cancer supportive care R&D pipeline overview
  • Table 4 Product profile: RN624 (tanezumab)
  • Table 5 Product profile: Rolontis
  • Table 6 Product profile: NEPA IV (Fosnetupitant and palonosetron fixed combination)
  • Table 7 Product profile: Anamorelin
  • Table 8 Product profile: HTX-011
  • Table 9 Product profile: Myelo001
  • Table 10 Most prevalent cancers using chemotherapy and/or radiation therapy as a treatment
  • option in the U.S. (2016)
  • Table 11 Patent expiry analysis
  • Table 12 Major products- G-CSF
  • Table 13 Major products- Erythropoietin stimulating agents
  • Table 14 Major products- Antiemetics
  • Table 15 Major products- Bisphosphonates
  • Table 16 Major products- Opioids and non-opioid
  • Table 17 Product Portfolio: Epogen (epoetin alfa)
  • Table 18 Product Portfolio: Neupogen (filgrastim)
  • Table 19 Product Portfolio: Aranesp (darbepoetin alfa)
  • Table 20 Product Portfolio: Neulasta (pegfilgrastim)
  • Table 21 Product Portfolio: Xgeva (denosumab)
  • Table 22 Product Portfolio: Emend (aprepitant)
  • Table 23 Product Portfolio: Procrit/ Eprex (epoetin alfa)
  • Table 24 Product Portfolio: Sustol (granisetron)
  • Table 25 Product Portfolio: Cinvanti (aprepitant)
  • Table 26 Product Portfolio: Zometa (zolederonic acid)
  • Table 27 Product Portfolio: Zarxio (filgrastim biosimilar)
  • Table 28 Product Portfolio: Varubi (rolapitant)
  • Table 29 Product Portfolio: NeoRecormon (epoetin beta)
  • Table 30 Product Portfolio: Aloxi (palonosetron)

List of Figures

  • Fig. 1 Cancer supportive care drugs market segmentation
  • Fig. 2 Cancer supportive care market snapshot
  • Fig. 3 Parent market outlook
  • Fig. 4 Ancillary market outlook
  • Fig. 5 Penetration & growth prospect mapping
  • Fig. 6 Reimbursement of cancer medicines (2016)
  • Fig. 7 Cancer supportive care drugs market driver impact
  • Fig. 8 Cancer supportive care drugs: market restraint impact
  • Fig. 9 Cancer supportive care drugs: Porter's Analysis
  • Fig. 10 Cancer supportive care drugs market: Drug class outlook key takeaways
  • Fig. 11 Drug class market share analysis (2018 & 2026)
  • Fig. 12 Cancer supportive care drugs market: Type movement analysis
  • Fig. 13 G-CSFs market, 2015 - 2026 (USD Million)
  • Fig. 14 ESAs market, 2015 - 2026 (USD Million)
  • Fig. 15 Antiemetics market, 2015 - 2026 (USD Million)
  • Fig. 16 Bisphosphonates market, 2015 - 2026 (USD Million)
  • Fig. 17 Opioids market, 2015 - 2026 (USD Million)
  • Fig. 18 NSAIDs and others market, 2015 - 2026 (USD Million)
  • Fig. 19 Regional market place, 2015 - 2026 (USD Million)
  • Fig. 20 Regional market share analysis (2018 & 2026)
  • Fig. 21 Regional market dashboard
  • Fig. 22 North America cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 23 Europe cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 24 Asia Pacific cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 25 Latin America cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 26 Middle East & Africa cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 27 North America cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 28 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 29 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 30 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 31 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 32 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 33 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 34 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 35 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 36 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 37 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 38 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 39 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 40 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 41 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 42 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 43 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 44 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 45 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 46 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 47 Middle East & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 48 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 49 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 50 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 51 Heat map analysis, by key market participants
  • Fig. 52 Key company market share analysis, 2018

The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.

Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market. High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.

G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.

Further key findings from the report suggest:

  • Some of the key market players are Amgen, Merck, Novartis, Johnson & Johnson, Roche, Helsinn Healthcare, Heron Pharma, Tesaro, and Purdue Pharma. Amgen led the global cancer supportive care market in 2018, capturing over 30% market share
  • By therapeutic class, the global ESAs market for CIA was valued at USD 1,838 million in 2018 and is expected to decline with a CAGR of 6.0% over the forecast period. The biologics segment is anticipated to lose its market share due to patent expiration of major brands such as Epogen
  • North America led the cancer supportive care drugs market in 2018 and is expected to maintain its position during the forecast period
  • Asia Pacific is expected to witness lucrative growth over the forecast period, owing to improvements in healthcare infrastructure and increasing government initiatives
  • Late stage pipeline products include non-opioids such as Tanezumab and HTX-011. Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
  • 1.2 Research Methodology
  • 1.3 Research Scope and Assumptions
  • 1.4 List to Data Sources
  • 1.5 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Related/ Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis, by Stage
  • 3.4 Clinical Profiles of Disruptive Drugs
  • 3.5 Regulatory Framework
  • 3.6 Market Dynamics
    • 3.6.1 Market Driver Analysis
      • 3.6.1.1 Growing cancer prevalence and increase in number of people receiving chemotherapy
      • 3.6.1.2 Large number of side effects associated with the cancer treatment
      • 3.6.1.3 Fundamental shift from branded biologics to biosimilar domination in cancer associated treatment
    • 3.6.2 Market Restraint Analysis
      • 3.6.2.1 Rising popularity of targeted therapies for the treatment of cancer in developed countries
      • 3.6.2.2 Unmet needs in cancer supportive care
      • 3.6.2.3 Safety issues associated with supportive care agents
  • 3.7 Patent Expiry Analysis
  • 3.8 Cancer Supportive Care Drugs Market: Market Analysis Tools
    • 3.8.1 Industry Analysis - Porter's
    • 3.8.2 major deals & strategic alliances analysis
      • 3.8.2.1 Joint Ventures
      • 3.8.2.2 Mergers & Acquistions
      • 3.8.2.3 Licensing & Partnership
      • 3.8.2.4 technology collaborations
    • 3.8.3 MARKET Dynamics and Brand STRATEGIES

Chapter 4 Cancer Supportive Care Drugs Market: Segment Analysis, by Drug Class, 2015 - 2026 (USD Million)

  • 4.1 Definitions & Scope
  • 4.2 Drug Class Market Share Analysis, 2018 & 2026
  • 4.3 Segment Dashboard
  • 4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following
    • 4.4.1 G-CSFs
      • 4.4.1.1 G-CSFs market, 2015 - 2026 (USD Million)
    • 4.4.2 Erythropoietin Stimulating Agents (ESA)
      • 4.4.2.1 Erythropoietin Stimulating Agents market, 2015 - 2026 (USD Million)
    • 4.4.3 Antiemetics
      • 4.4.3.1 Antiemetics market, 2015 - 2026 (USD Million)
    • 4.4.4 Bisphosphonates
      • 4.4.4.1 Bisphosphonates market, 2015 - 2026 (USD Million)
    • 4.4.5 Opioids
      • 4.4.5.1 opioids market, 2015 - 2026 (USD Million)
    • 4.4.6 NSAIDs and Others
      • 4.4.6.1 NSAIDs and Others market, 2015 - 2026 (USD Million)

Chapter 5 Cancer Supportive Care Drugs Market: Regional Market Analysis

  • 5.1 Regional Market Share Analysis, 2018 & 2026
  • 5.2 Regional Market Dashboard
  • 5.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
    • 5.3.1 North america
    • 5.3.2 Europe
    • 5.3.3 Asia pacific
    • 5.3.4 Latin America
    • 5.3.5 Middle east & africa
  • 5.4 Market Size & Forecasts, Estimates and Trend Analysis, 2018 to 2026
  • 5.5 North America
    • 5.5.1 North america cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.1.1 U.S.
      • 5.5.1.2 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.1.3 Canada
      • 5.5.1.4 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.2 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.1 U.K.
      • 5.5.2.2 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.3 Germany
      • 5.5.2.4 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.5 France
      • 5.5.2.6 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.7 Italy
      • 5.5.2.8 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.9 Spain
      • 5.5.2.10 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.3 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.1 CHINA
      • 5.5.3.2 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.3 India
      • 5.5.3.4 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.5 Japan
      • 5.5.3.6 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.7 Thailand
      • 5.5.3.8 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.9 South Korea
      • 5.5.3.10 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.4 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.1 Brazil
      • 5.5.4.2 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.3 Mexico
      • 5.5.4.4 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.5 Argentina
      • 5.5.4.6 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.7 Colombia
      • 5.5.4.8 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.5 Middle east & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.5.1 South Africa
      • 5.5.5.2 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.5.3 Saudi Arabia
      • 5.5.5.4 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.5.5 UAE
      • 5.5.5.6 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)

Chapter 6 Cancer Supportive Care Drugs Market - Competitive Analysis

  • 6.1 Recent Developments & Impact analysis, by key market participants
  • 6.2 Company Categorization
    • 6.2.1 Market Leader
    • 6.2.2 Key innovators
    • 6.2.3 Emerging Players
      • 6.2.3.1 Pfizer (Hospira)
      • 6.2.3.2 Heron Therapeutics
      • 6.2.3.3 Spectrum Pharmaceuticals
      • 6.2.3.4 Myelo Therapeutics
  • 6.3 Vendor Landscape
    • 6.3.1 Key Customers
    • 6.3.2 Key Company market share analysis, 2018
  • 6.4 Key Companies Profiled
    • 6.4.1 Amgen Inc.
      • 6.4.1.1 Company overview
      • 6.4.1.2 Financial Performance
      • 6.4.1.3 product benchmarking
      • 6.4.1.4 recent developments
    • 6.4.2 Merck & Co.
      • 6.4.2.1 Company Overview
      • 6.4.2.2 Financial Performance
      • 6.4.2.3 Product benchmarking
      • 6.4.2.4 Recent developments
    • 6.4.3 Johnson & Johnson SeRvices, Inc.
      • 6.4.3.1 Company Overview
      • 6.4.3.2 Financial Performance
      • 6.4.3.3 Product benchmarking
      • 6.4.3.4 Recent developments
    • 6.4.4 Heron Therapeutics, Inc.
      • 6.4.4.1 Company Overview
      • 6.4.4.2 Financial Performance
      • 6.4.4.3 Product benchmarking
      • 6.4.4.4 Recent developments
    • 6.4.5 NOVARTIS AG
      • 6.4.5.1 Company Overview
      • 6.4.5.2 Financial Performance
      • 6.4.5.3 Product benchmarking
      • 6.4.5.4 Recent developments
    • 6.4.6 TESARO, Inc.
      • 6.4.6.1 Company Overview
      • 6.4.6.2 Financial Performance
      • 6.4.6.3 Product benchmarking
      • 6.4.6.4 Recent developments
    • 6.4.7 F. Hoffmann-La Roche AG
      • 6.4.7.1 Company Overview
      • 6.4.7.2 Financial Performance
      • 6.4.7.3 Product benchmarking
      • 6.4.7.4 Recent developments
    • 6.4.8 HELSINN Healthcare SA
      • 6.4.8.1 Company Overview
      • 6.4.8.2 Product benchmarking
      • 6.4.8.3 Recent developments
Back to Top
전화 문의
F A Q